Availability and use of parenteral quinidine gluconate for severe or complicated malaria.
Since 1991, quinidine gluconate, a class 1a anti-arrhythmic agent, has been the only parenteral antimalarial available for use in the United States (1). It is indicated for the treatment of patients with life-threatening Plasmodium falciparum malaria (2), including those who cannot tolerate oral therapy, have high-grade parasitemia, or have complications (e.g., cerebral malaria or acute renal failure).
D000962:Antimalarials / Q000600:supply & distribution* / Q000627:therapeutic use*; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D011802:Quinidine / Q000031:analogs & derivatives* / Q000600:supply & distribution* / Q000627:therapeutic use*; D014481:United States
D000962:Antimalarials; D011802:Quinidine; C016713:quinidine gluconate